Lars C. Borris

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. · New England Journal of Medicine · 2008 · 1.4K citations · Full text

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

Michael R. Lassen, Walter Ageno, Lars C. Borris et al. · New England Journal of Medicine · 2008 · 1.3K citations · Full text

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl et al. · Circulation · 2006 · 332 citations · Full text

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement

Bengt I. Eriksson, Lars C. Borris, O.E. Dahl et al. · Journal of Thrombosis and Haemostasis · 2005 · 300 citations · Full text

Thrombosis, Venous Thrombosis, Hematology +8

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Wolfgang Mueck, Bengt I. Eriksson, Kenneth A. Bauer et al. · Clinical Pharmacokinetics · 2008 · 242 citations

Medicine, Orthopaedics, Clinical Pharmacology +7